Pathalys Pharma, Inc.

About Pathalys Pharma, Inc.

Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company dedicated to improving the lives of patients with chronic kidney disease (CKD) by developing advanced therapeutics to address unmet needs in the management of late-stage CKD.

Products & Services

Upacicalcet:A novel calcimimetic for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage kidney disease. It is delivered intravenously via pre-filled syringe at the end of hemodialysis sessions, effectively reducing parathyroid hormone (PTH) levels with a potentially better tolerability profile.

Specialties

Chronic Kidney Disease (CKD) management End-stage kidney disease treatments Secondary Hyperparathyroidism (SHPT) treatment Calcimimetic therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 105000000 MR: - FA: $105 million FAN: 105000000	D: 2024-08-20 FD: 2024-08-20	8 investors
2	RT: Secured Product Financing and Equity T: - FT: Secured Product Financing and Equity	A: 150000000 MR: - FA: $150 Million FAN: 150000000	D: 2023-01-18 FD: 2023-01-18	5 investors

Series B Latest

2024-08-20

$105.0M

8 investors (Pro only)

Secured Product Financing and Equity 2023-01-18

$150.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Neal Fowler

Chief Executive Officer

P

Patrick Treanor

Chief Operating Officer

B

Bastian Dehmel

Chief Medical Officer

D

David Banks

Senior Vice President, Technical Operations

G

Greg Klatt

SVP Finance

P

Pam Danagher

SVP Head of Regulatory Affairs

View 7 more team members with Pro

Unlock Full Team Directory

Recent News